Rate of change in renal function and mortality in elderly treated hypertensive patients

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 7, 2015, Pages 1154-1161

  Chowdhury, Enayet K ^a   Langham, Robyn G ^b   Ademi, Zanfina ^a   Owen, Alice ^a,b   Krum, Henry ^a   Wing, Lindon M H ^c   Nelson, Mark R ^d   Reid, C M ^e   Wing, L ^e   Beilin, L J ^e   Brown, M A ^e   Jennings, G ^e   Johnston, C I ^e   McNeil, J J ^e   Marley, J E ^e   Morgan, T O ^e   Ryan, P ^e   Shaw, J ^e   West, M J ^e   MacDonald, G ^e  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

^d UNIVERSITY OF TASMANIA   (Australia)

^e University of Tasmania ^*

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER;

AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; AGE; AUSTRALIA; BLOOD; DRUG EFFECTS; KIDNEY; MORTALITY; ODDS RATIO; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; AUSTRALIA; BIOMARKERS; BLOOD PRESSURE; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY; LOGISTIC MODELS; MALE; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84936867267     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.07370714     Document Type: Article

References (44)

1. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF, Matsushita K, Wen CP: Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. Lancet 382: 339-352, 2013
2. World Health Organization: Global Status Report on Noncommunicable Diseases 2010, Geneva, Switzerland, World Health Organization, 2011
3. Couser WG, Remuzzi G, Mendis S, Tonelli M: The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int 80: 1258-1270, 2011
4. Fried LF, Shlipak MG, Crump C, Bleyer AJ, Gottdiener JS, Kronmal RA, Kuller LH, Newman AB: Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 41: 1364-1372, 2003
5. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, Gardin JM, Rutledge JE, Boineau RC: Predictors of congestive heart failure in the elderly: The Cardiovascular Health Study. J Am Coll Cardiol 35: 1628-1637, 2000
6. Brugts JJ, Knetsch AM, Mattace-Raso FU, Hofman A, Witteman JC: Renal function and risk of myocardial infarction in an elderly population: TheRotterdam Study. Arch InternMed 165: 2659-2665, 2005
7. O’Hare AM, Choi AI, Bertenthal D, Bacchetti P, Garg AX, Kaufman JS, Walter LC, Mehta KM, Steinman MA, Allon M, McClellan WM, Landefeld CS: Age affects outcomes in chronic kidney disease. J Am Soc Nephrol 18: 2758-2765, 2007
8. Glassock RJ, Rule AD: The implications of anatomical and functional changes of the aging kidney: With an emphasis on the glomeruli. Kidney Int 82: 270-277, 2012
9. Shlipak MG, Katz R, Kestenbaum B, Siscovick D, Fried L, Newman A, Rifkin D, Sarnak MJ: Rapid decline of kidney function increases cardiovascular risk in the elderly. J Am Soc Nephrol 20: 2625-2630, 2009
10. Rifkin DE, Shlipak MG, Katz R, Fried LF, Siscovick D, Chonchol M, NewmanAB, SarnakMJ:Rapid kidney function decline andmortality risk in older adults. Arch Intern Med 168: 2212-2218, 2008
11. Matsushita K, Selvin E, Bash LD, Franceschini N, Astor BC, Coresh J: Change in estimated GFR associates with coronary heart disease and mortality. J Am Soc Nephrol 20: 2617-2624, 2009
12. Turin TC, Coresh J, Tonelli M, Stevens PE, de Jong PE, Farmer CK, Matsushita K, Hemmelgarn BR: Change in the estimated glomerular filtration rate over time and risk of all-causemortality. Kidney Int 83: 684-691, 2013
13. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, Levey AS: The effect of a lower target blood pressure on the progression of kidney disease: Long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 142: 342-351, 2005
14. Davis EM, Appel LJ, Wang X, Greene T, Astor BC, Rahman M, Toto R, Lipkowitz MS, Pogue VA, Wright JT Jr; African American Study of Kidney Disease and Hypertension Research Collaborative Group: Limitations of analyses based on achieved blood pressure: Lessons from the African American study of kidney disease and hypertension trial. Hypertension 57: 1061-1068, 2011
15. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS; AIPRD Study Group: Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 139: 244-252, 2003
16. Rao MV, Qiu Y, Wang C, Bakris G: Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am J Kidney Dis 51[Suppl 2]: S30-S37, 2008
17. Wright Jr JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288: 2421- 2431, 2002
18. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, Lesti M, Perticucci E, Chakarski IN, Leonardis D, Garini G, Sessa A, Basile C, Alpa M, Scanziani R, Sorba G, Zoccali C, Remuzzi G; REIN-2 Study Group: Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): Multicentre, randomised controlled trial. Lancet 365: 939-946, 2005
19. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ: Effect of inhibitors of the reninangiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet 366: 2026-2033, 2005
20. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ; Second Australian National Blood Pressure Study Group: A comparison of outcomes with angiotensin-converting- enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348: 583-592, 2003
21. Johnson DW, Jones GR, Mathew TH, Ludlow MJ, Doogue MP, Jose MD, Langham RG, Lawton PD, McTaggart SJ, Peake MJ, Polkinghorne K, Usherwood T; Australasian Creatinine ConsensusWorking Group: Chronic kidney disease and automatic reportingof estimated glomerular filtration rate:Newdevelopments and revised recommendations. Med J Aust 197: 224-225, 2012
22. Uhlig K, Macleod A, Craig J, Lau J, Levey AS, Levin A, Moist L, Steinberg E, Walker R, Wanner C, Lameire N, Eknoyan G: Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 70: 2058-2065, 2006
23. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009
24. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration: Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53: 766-772, 2007
25. Skali H, Uno H, Levey AS, Inker LA, Pfeffer MA, Solomon SD: Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation. Am Heart J 162: 548-554, 2011
26. StataCorp: Stata Statistical Software: Release 11, College Station, TX, StataCorp, 2009
27. Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, Chambless LE, Coresh J: Reduced kidney function as a risk factor for incident heart failure: The atherosclerosis risk in communities (ARIC) study. J AmSoc Nephrol 18: 1307-1315, 2007
28. Perkins RM, Bucaloiu ID, Kirchner HL, Ashouian N, Hartle JE, Yahya T: GFR decline and mortality risk among patients with chronic kidney disease.Clin JAmSocNephrol 6: 1879-1886, 2011
29. Hemmelgarn BR, Zhang J, Manns BJ, Tonelli M, Larsen E, Ghali WA, Southern DA, McLaughlin K, Mortis G, Culleton BF: Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int 69: 2155-2161, 2006
30. Rosario RF, Wesson DE: Primary hypertension and nephropathy. Curr Opin Nephrol Hypertens 15: 130-134, 2006
31. Wasén E, Isoaho R, Mattila K, Vahlberg T, Kivelä SL, Irjala K: Renal impairment associated with diabetes in the elderly. Diabetes Care 27: 2648-2653, 2004
32. Izzo JL Jr, Shykoff BE: Arterial stiffness: clinical relevance, measurement, and treatment. Rev Cardiovasc Med 2: 29-34, 37-40, 2001
33. Australian Institute of Health and Welfare: Rural Health Series No 10. Cat. No. PHE 103. Rural, Regional and Remote Health: Indicators of Health System Performance, Canberra, Australia, Australian Institute of Health and Welfare, 2008
34. Trevisan R, Dodesini AR, Lepore G: Lipids and renal disease. J Am Soc Nephrol 17[Suppl 2]: S145-S147, 2006
35. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F; ACCORD Study Group: Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362: 1575-1585, 2010
36. Basile DP, Donohoe D, Roethe K, Osborn JL: Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. Am J Physiol Renal Physiol 281: F887-F899, 2001
37. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members: 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 31: 1281-1357, 2013
38. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter BL, Materson BJ, Ram CVS, Cohen DL, Cadet JC, Jean-Charles RR, Taler S, Kountz D, Townsend R, Chalmers J, Ramirez AJ, Bakris GL, Wang J, Schutte AE, Bisognano JD, Touyz RM, Sica D, Harrap SB: Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 32: 3-15, 2014
39. Law MR, Morris JK, Wald NJ: Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338: b1665, 2009
40. Ruilope LM, Schiffrin EL: Blood pressure control and benefits of antihypertensive therapy:Does it make a difference which agents we use? Hypertension 38: 537-542, 2001
41. Malacco E, Omboni S, Mallion JM, Volpe M, Group ES; ESPORT Study Group: Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patientswithmild tomoderate hypertension grouped according to renal function status: a retrospective analysis. High Blood Press Cardiovasc Prev 19: 213-222, 2012
42. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS; Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association: Renal considerations in angiotensin converting enzyme inhibitor therapy: A statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 104: 1985-1991, 2001
43. Hall JE, Guyton AC, Jackson TE, Coleman TG, Lohmeier TE, Trippodo NC: Control of glomerular filtration rate by reninangiotensin system. Am J Physiol 233: F366-F372, 1977
44. Matsushita K, Selvin E, Bash LD, Astor BC, Coresh J: Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 55: 648-659, 2010